CISEN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.98 CNY | +2.46% |
|
+1.08% | +2.32% |
| 2023 | Cisen Pharmaceutical Scraps Unit Spin-Off Plan | CI |
| 2023 | Cisen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
| Sales 2021 | 3.78B 523M | Sales 2022 | 4.07B 562M | Capitalization | 5.67B 783M |
|---|---|---|---|---|---|
| Net income 2021 | 334M 46.16M | Net income 2022 | 350M 48.37M | EV / Sales 2021 | 0.98 x |
| Net cash position 2021 | 2.28B 315M | Net cash position 2022 | 2.63B 363M | EV / Sales 2022 | 0.75 x |
| P/E ratio 2021 |
18
x | P/E ratio 2022 |
16.4
x | Employees | 3,413 |
| Yield 2021 |
2.25% | Yield 2022 |
2.66% | Free-Float | 37.54% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.46% | ||
| 1 week | +1.08% | ||
| Current month | +4.32% | ||
| 1 month | +4.32% | ||
| 3 months | -3.97% | ||
| 6 months | +12.21% | ||
| Current year | +2.32% |
1 week
14.52
15.46
1 month
13.8015.46
Current year
11.3416.41
1 year
11.3416.93
3 years
10.3016.93
5 years
10.3020.65
10 years
10.3032.73
| Managers | Title | Age | Since |
|---|---|---|---|
Zhen Xin Du
CEO | Chief Executive Officer | 57 | 98-11-05 |
En Long Zhao
CHM | Chairman | 45 | 04-06-30 |
Xiang Liu
BRD | Director/Board Member | 35 | 17-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hong Zhang
BRD | Director/Board Member | 59 | 17-11-27 |
Zhen Xin Du
CEO | Chief Executive Officer | 57 | 98-11-05 |
Xin Sheng Sun
BRD | Director/Board Member | 71 | 17-11-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 14.98 | +2.46% | 3,870,760 |
| 24-04-16 | 14.62 | -3.31% | 4,434,775 |
| 24-04-15 | 15.12 | -0.46% | 3,204,208 |
| 24-04-12 | 15.19 | -0.52% | 3,062,652 |
| 24-04-11 | 15.27 | +3.04% | 4,062,500 |
End-of-day quote Shanghai S.E., April 16, 2024
More quotes
Cisen Pharmaceutical Co., Ltd is a China-based company principally involved in the research, development, manufacturing and sales of medical products. The Company operates through two main segments. The Main Business segment is primarily involved in the manufacturing and sales of medicine, among which include infusion, freeze-dried powder, small volume injection, tablet, capsules, ointment, drops and active pharmaceutical ingredients, among others. The Other Business segment is mainly involved in the sales of raw materials and houses tenancy.
Sector
Pharmaceuticals
Calendar
2024-04-22
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +2.32% | 933M | |
| +21.93% | 44.1B | |
| +17.91% | 21.97B | |
| +10.48% | 13.27B | |
| +3.70% | 13.22B | |
| +37.38% | 11.36B | |
| -8.25% | 7.07B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.09% | 5.23B |
- Stock Market
- Equities
- 603367 Stock
